Genflow Biosciences PLC Announces Key SIRT6 Patent Application
Genflow Biosciences (LSE:GENF)(OTCQB:GENFF) announces the advancement of its SIRT6-related patent application to the national examination phase by the Japanese Patent Office. The patent, titled "Variants of SIRT6 for Use in Preventing and/or Treating Age-Related Diseases," was filed in May 2022 and is jointly owned by the University of Rochester, Columbia University, and Albert Einstein College of Medicine, with Genflow holding exclusive licensing rights.
The patent covers novel SIRT6 gene variants crucial for genomic stability, metabolic regulation, and healthy aging, forming the foundation of Genflow's therapeutic platform. This advancement in Japan, a key market with a rapidly aging population, represents a significant step in the company's international patent protection strategy.
Genflow Biosciences (LSE:GENF)(OTCQB:GENFF) annuncia il passaggio della sua domanda di brevetto relativa a SIRT6 alla fase di esame nazionale presso l'Ufficio Brevetti Giapponese. Il brevetto, intitolato "Varianti di SIRT6 per l'uso nella prevenzione e/o nel trattamento delle malattie legate all'invecchiamento", 猫 stato depositato nel maggio 2022 ed 猫 di propriet脿 congiunta dell'Universit脿 di Rochester, della Columbia University e dell'Albert Einstein College of Medicine, con Genflow che detiene i diritti di licenza esclusiva.
Il brevetto riguarda nuove varianti del gene SIRT6, fondamentali per la stabilit脿 genomica, la regolazione metabolica e un invecchiamento sano, costituendo la base della piattaforma terapeutica di Genflow. Questo progresso in Giappone, un mercato chiave con una popolazione in rapido invecchiamento, rappresenta un passo importante nella strategia internazionale di protezione brevettuale dell'azienda.
Genflow Biosciences (LSE:GENF)(OTCQB:GENFF) anuncia el avance de su solicitud de patente relacionada con SIRT6 a la fase de examen nacional por parte de la Oficina de Patentes de Jap贸n. La patente, titulada "Variantes de SIRT6 para su uso en la prevenci贸n y/o tratamiento de enfermedades relacionadas con la edad", fue presentada en mayo de 2022 y es propiedad conjunta de la Universidad de Rochester, la Universidad de Columbia y el Albert Einstein College of Medicine, con Genflow poseyendo los derechos exclusivos de licencia.
La patente cubre nuevas variantes del gen SIRT6, cruciales para la estabilidad gen贸mica, la regulaci贸n metab贸lica y un envejecimiento saludable, que forman la base de la plataforma terap茅utica de Genflow. Este avance en Jap贸n, un mercado clave con una poblaci贸n que envejece r谩pidamente, representa un paso significativo en la estrategia internacional de protecci贸n de patentes de la compa帽铆a.
Genflow Biosciences (LSE:GENF)(OTCQB:GENFF)電� 鞚茧掣 韸鬼棃觳棎靹� SIRT6 甏�霠� 韸鬼棃 於滌洂鞚� 甑皜 鞁偓 雼硠搿� 歆勳爠霅橃棃鞚岇潉 氚滍憸頄堨姷雼堧嫟. "雲疙檾 甏�霠� 歆堧硲 鞓堧癌 氚�/霕愲姅 旃橂鞐� 靷毄霅橂姅 SIRT6 氤�鞚挫泊"霛茧姅 鞝滊鞚� 鞚� 韸鬼棃電� 2022雲� 5鞗旍棎 於滌洂霅橃棃鞙茧┌ 搿滌泊鞀ろ劙 雽�頃欔祼, 旖滊‖牍勳晞 雽�頃欔祼, 鞎岆矂韸� 鞎勳澑鞀堩儉鞚� 鞚橁臣雽�頃欖澊 瓿惦彊 靻岇湢頃橁碃 鞛堨溂氅�, Genflow臧� 霃呾爯 霛检澊靹犾姢 甓岆Μ毳� 氤挫湢頃橁碃 鞛堨姷雼堧嫟.
鞚� 韸鬼棃電� 鞙犾爠觳� 鞎堨爼靹�, 雽�靷� 臁办爤 氚� 瓯搓皶頃� 雲疙檾鞐� 欷戩殧頃� 靸堧鞖� SIRT6 鞙犾爠鞛� 氤�鞚挫泊毳� 韽暔頃橂┌, Genflow鞚� 旃橂 頂岆灚韽检潣 旮办磮毳� 順曥劚頃╇媹雼�. 旮夓啀頌� 瓿犽牴頇旊悩電� 鞚戈惮毳� 臧�歆� 欤检殧 鞁滌灔鞚� 鞚茧掣鞐愳劀鞚� 鞚措矆 歆勳爠鞚� 須岇偓鞚� 甑牅 韸鬼棃 氤错樃 鞝勲灥鞐� 欷戩殧頃� 雼硠鞛呺媹雼�.
Genflow Biosciences (LSE:GENF)(OTCQB:GENFF) annonce l鈥檃vancement de sa demande de brevet li茅e 脿 SIRT6 脿 la phase d鈥檈xamen national par l鈥橭ffice des brevets japonais. Le brevet, intitul茅 芦 Variantes de SIRT6 pour une utilisation dans la pr茅vention et/ou le traitement des maladies li茅es 脿 l鈥櫭e 禄, a 茅t茅 d茅pos茅 en mai 2022 et est d茅tenu conjointement par l鈥橴niversit茅 de Rochester, l鈥橴niversit茅 de Columbia et le Albert Einstein College of Medicine, Genflow d茅tenant les droits exclusifs de licence.
Le brevet couvre de nouvelles variantes du g猫ne SIRT6, essentielles pour la stabilit茅 g茅nomique, la r茅gulation m茅tabolique et un vieillissement en bonne sant茅, constituant la base de la plateforme th茅rapeutique de Genflow. Cette avanc茅e au Japon, un march茅 cl茅 avec une population vieillissante rapidement, repr茅sente une 茅tape importante dans la strat茅gie internationale de protection par brevet de la soci茅t茅.
Genflow Biosciences (LSE:GENF)(OTCQB:GENFF) gibt bekannt, dass seine SIRT6-bezogene Patentanmeldung von der japanischen Patentbeh枚rde in die nationale Pr眉fungsphase 眉bergegangen ist. Das Patent mit dem Titel "Varianten von SIRT6 zur Verwendung bei der Vorbeugung und/oder Behandlung altersbedingter Krankheiten" wurde im Mai 2022 eingereicht und befindet sich im gemeinsamen Eigentum der University of Rochester, der Columbia University und des Albert Einstein College of Medicine, wobei Genflow exklusive Lizenzrechte h盲lt.
Das Patent umfasst neuartige SIRT6-Genvarianten, die f眉r die genomische Stabilit盲t, Stoffwechselregulation und gesundes Altern entscheidend sind und die Grundlage der therapeutischen Plattform von Genflow bilden. Dieser Fortschritt in Japan, einem wichtigen Markt mit schnell alternder Bev枚lkerung, stellt einen bedeutenden Schritt in der internationalen Patentstrategie des Unternehmens dar.
- Exclusive licensing rights secured for SIRT6 patent application
- Strategic expansion of patent protection in Japan, a key market for longevity treatments
- Advancement to national examination phase indicates patent progress
- Patent is still in examination phase, not yet granted
- Patent ownership is shared between multiple institutions
LONDON, UNITED KINGDOM / / May 15, 2025 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company"), the only publicly listed longevity company in Europe, announces that the Japanese Patent Office has advanced its SIRT6-related patent application (Application No. JP 2024515284) to the national examination phase.
The application, titled "Variants of SIRT6 for Use in Preventing and/or Treating Age-Related Diseases," was originally filed on 13 May 2022 and is jointly owned by the University of Rochester, The Trustees of Columbia University in the City of New York, and Albert Einstein College of Medicine. Genflow holds the exclusive license to this intellectual property.
The invention covers novel SIRT6 gene variants that play a central role in genomic stability, metabolic regulation, and healthy aging. These variants underpin Genflow's core therapeutic platform and represent a key part of its pipeline targeting age-related diseases.
The progression to national examination in Japan marks an important step in Genflow's strategy to establish broad international patent protection. Japan, with one of the world's most rapidly aging populations, is a priority market for longevity-related innovation.
Dr. Eric Leire, CEO of Genflow Biosciences, commented: "We are pleased to see continued momentum in the protection of our SIRT6 intellectual property. Japan represents a strategically important jurisdiction for Genflow, and advancing this patent application strengthens our global positioning as a leader in longevity gene therapy."
Genflow continues to progress its preclinical and clinical programs targeting age-related pathologies using the SIRT6 gene variants.
Contacts
Genflow Biosciences | Harbor Access | ||
Dr Eric Leire, CEO | Jonathan Paterson, Investor Relations | ||
+32-477-495-881 | +1 475 477 9401 | ||
Corporate Brokers | |||
Capital Plus Partners Ltd | |||
Jon Critchley, +44 0203 821 6168 | |||
About Genflow Biosciences
Founded in 2020, Genflow Biosciences Plc. (LSE:GENF)(OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies to decelerate the aging process, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population. Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising preclinical results. Expected to begin in 2025, Genflow's clinical trial aims to explore the potential benefits of GF-1002 in treating MASH (Metabolic Dysfunction-Associated Steatohepatitis), the most prevalent chronic liver disease for which there is no effective treatments. Please visit and follow the Company on LinkedIn and Twitter/X.
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit .
SOURCE: Genflow Biosciences PLC
View the original on ACCESS Newswire
FAQ
What is the significance of GENFF's SIRT6 patent application in Japan?
Who owns the SIRT6 patent application filed by Genflow Biosciences?
What is the potential market impact of GENFF's SIRT6 technology?
When was Genflow's SIRT6 patent application originally filed?
